The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Observational study of the first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial.
Kei Muro
Honoraria - Bristol-Myers Squibb; Merck Serono
Michio Itabashi
Honoraria - Bristol-Myers Squibb; Merck Serono
Hiroki Hashida
Honoraria - Merck Serono
Toshiki Masuishi
Honoraria - Bristol-Myers Squibb
Masanori Kotake
Honoraria - Merck KGaA
Tadamichi Denda
Honoraria - Bristol-Myers Squibb; Merck Serono
Yasuo Ohashi
No relevant relationships to disclose
Kenichi Sugihara
Honoraria - Bristol-Myers Squibb; Merck Serono